Earnings History Data for Allogene Therapeutics, Inc. (ALLO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-03-2024	AH		ALLO	Allogene Therapeutics, Inc.	824.56	-0.43	-0.47	-0.66	Allogene Therapeutics GAAP EPS of -$0.51 misses by $0.06 [3/14/2024 4:24 PM]	4.66	0.16 (3.56%)	4.48	-0.01 (-0.33%)	2.23 - 6.89	3,700,061	2,440,000	624
Allogene Therapeutics GAAP EPS of -$0.51 misses by $0.06 [3/14/2024 4:24 PM] Allogene Therapeutics files for $500M mixed shelf [3/14/2024 5:37 PM]
02-11-2023	AH		ALLO	Allogene Therapeutics, Inc.	472.71	-0.37	-0.53	-0.58	Allogene Therapeutics GAAP EPS of $0.37 beats by $0.89, revenue of $0.04M beats by $0.03M [11/2/2023 4:08 PM]	3.52	0.55 (18.69%)	3.00	0.03 (1.01%)	2.53 - 11.10	3,075,909	1,300,000	1,292
Allogene Therapeutics GAAP EPS of $0.37 beats by $0.89, revenue of $0.04M beats by $0.03M [11/2/2023 4:08 PM] Allogene shares rally 22% amid Q3 report, medical meeting presentations [11/3/2023 1:17 PM]
02-08-2023	AH		ALLO	Allogene Therapeutics, Inc.	723.37	-0.53	-0.59	-0.52	Allogene Therapeutics GAAP EPS of -$0.53 beats by $0.06, revenue of $0.04M beats by $0.02M [8/2/2023 4:09 PM]	5.17	0.48 (10.23%)	4.79	0.10 (2.13%)	4.30 - 17.49	7,685,705	1,690,000	12,555
Allogene Therapeutics GAAP EPS of -$0.53 beats by $0.06, revenue of $0.04M beats by $0.02M [8/2/2023 4:09 PM]
03-05-2023	AH	4:00 PM ET (May 3)	ALLO	Allogene Therapeutics, Inc.	806.17	-0.68	-0.63	-0.56	Allogene Therapeutics GAAP EPS of -$0.68 misses by $0.06, revenue of $0.05M beats by $0.04M [5/3/2023 4:35 PM]	6.46	0.74 (12.85%)	5.65	-0.07 (-1.22%)	4.42 - 17.49	6,462,513	2,530,000	65,561
Allogene Therapeutics GAAP EPS of -$0.68 misses by $0.06, revenue of $0.05M beats by $0.04M [5/3/2023 4:35 PM]
28-02-2023	AH	4:00 PM ET (Feb 28)	ALLO	Allogene Therapeutics, Inc.	969.09	-0.66	-0.71	-0.54	Allogene Therapeutics GAAP EPS of -$0.66 beats by $0.04, revenue of $0.05M misses by $0.01M [2/28/2023 4:06 PM]	6.33	-0.01 (-0.24%)	6.23	-0.12 (-1.89%)	5.41 - 17.49	2,197,331	1,700,000	575
Allogene Therapeutics GAAP EPS of -$0.66 beats by $0.04, revenue of $0.05M misses by $0.01M [2/28/2023 4:06 PM]
02-11-2022	AH	4:00 PM ET (Nov 2)	ALLO	Allogene Therapeutics, Inc.	1,480	-0.58	-0.62	-0.57	Allogene Therapeutics GAAP EPS of -$0.58 beats by $0.06, revenue of $0.05M beats by $0.04M [11/2/2022 4:35 PM]	9.54	-0.63 (-6.24%)	10.17	0.0 (0.00%)	6.42 - 20.75	3,199,252	1,120,000	18,323
Allogene Therapeutics GAAP EPS of -$0.58 beats by $0.06, revenue of $0.05M beats by $0.04M [11/2/2022 4:35 PM] Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase [Nov-02-22 04:02PM] Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates [Nov-02-22 05:25PM] Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology [Nov-03-22 09:04AM]
09-08-2022	AH	4:00 PM ET (Aug 9)	ALLO	Allogene Therapeutics, Inc.	1,920	-0.52	-0.61	-0.53	Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M [8/9/2022 4:12 PM]	16.23	1.20 (7.98%)	14.85	-0.18 (-1.20%)	6.42 - 27.86	2,215,900	1,540,000	2,788
Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M [8/9/2022 4:12 PM] Allogene downgraded to market perform from outperform at Raymond James [8/10/2022 11:58 AM] Allogene stock rises on Q2 beat despite downgrade at Raymond James; eyes FDA nod for ALLO-501A trial in 'coming weeks' [8/10/2022 1:42 PM] Allogene Therapeutics Reports Second Quarter 2022 Financial Results [Aug-09-22 04:02PM] Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates [Aug-09-22 05:25PM]
04-05-2022	AH	4:00 PM ET (May 4)	ALLO	Allogene Therapeutics	1,199	-0.56	-0.59	0.00	Allogene Therapeutics GAAP EPS of -$0.56 beats by $0.02 [5/4/2022 4:37 PM]	9.28	-0.15 (-1.59%)	9.75	0.32 (3.39%)	7.48 - 31.77	2,433,407	2,210,000	619
Allogene Therapeutics GAAP EPS of -$0.56 beats by $0.02 [5/4/2022 4:37 PM] Allogene Therapeutics Reports First Quarter 2022 Financial Results [May-04-22 04:02PM] Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates [May-04-22 05:15PM]
23-02-2022	AH	4:00 PM ET (Feb 23)	ALLO	Allogene Therapeutics, Inc.	1,330	-0.54	-0.61	-0.53	Allogene Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $51M [2/23/2022 4:26 PM]	9.20	0.03 (0.33%)	8.96	-0.21 (-2.29%)	8.33 - 39.12	2,891,183	1,506,745	23,087
Allogene Therapeutics GAAP EPS of -$0.54 beats by $0.06, revenue of $51M [2/23/2022 4:26 PM] Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update [Feb-23-22 04:02PM] Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies [Feb-24-22 10:37AM]
04-11-2021	AH	4:00 PM ET (Nov 4)	ALLO	Allogene Therapeutics, Inc.	2,660	-0.57	-0.56	-0.52	Allogene Therapeutics EPS misses by $0.01 [11/4/2021 4:38 PM]	20.12	0.70 (3.58%)	20.00	0.57 (2.93%)	12.90 - 39.12	1,647,810	1,440,000	2,042
Allogene Therapeutics EPS misses by $0.01 [11/4/2021 4:38 PM] SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO [Nov-04-21 02:24AM] Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T Trials at the 63rd Annual Meeting of the American Society of Hematology [Nov-04-21 09:05AM] Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update [Nov-04-21 04:02PM] Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript [Nov-05-21 10:31AM] Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold [Nov-05-21 11:19AM]
04-08-2021	AH	4:00 PM ET (Aug 4)	ALLO	Allogene Therapeutics, Inc.	3,200	-0.53	-0.55	-0.53	Allogene Therapeutics EPS beats by $0.02, misses on revenue [8/4/2021 4:32 PM]	23.73	1.60 (7.21%)	22.13	0.0 (0.00%)	21.10 - 44.92	973,111	510,000	23,096
Allogene Therapeutics EPS beats by $0.02, misses on revenue [8/4/2021 4:32 PM] Would Shareholders Who Purchased Allogene Therapeutics' (NASDAQ:ALLO) Stock Year Be Happy With The Share price Today? [Aug-03-21 01:25AM] Allogene Therapeutics Reports Second Quarter 2021 Financial Results [Aug-04-21 04:02PM] Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances [Aug-05-21 09:57AM]
05-05-2021	AH	4:00 PM ET (May 5)	ALLO	Allogene Therapeutics, Inc.	4,370	-0.25	-0.48	-0.50	Allogene Therapeutics EPS beats by $0.21, beats on revenue [5/5/2021 4:26 PM]	29.15	0.44 (1.53%)	29.19	0.48 (1.67%)	24.85 - 55.00	1,111,254	670,000	64,869
Allogene Therapeutics (NASDAQ:ALLO) Is In A Strong Position To Grow Its Business [May-05-21 01:36AM] Allogene Therapeutics, Inc. to Host Earnings Call [May-05-21 03:15PM] Allogene Therapeutics Reports First Quarter 2021 Financial Results [May-05-21 04:02PM] Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances [May-06-21 10:24AM] Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates [May-05-21 06:05PM]
25-02-2021	AH	After the close (Feb 25)	ALLO	Allogene Therapeutics, Inc.	4,740	-0.53	-0.56	-0.58	Allogene Therapeutics EPS beats by $0.05 [2/25/2021 4:35 PM]	34.91	2.12 (6.47%)	34.44	1.65 (5.03%)	17.43 - 55.00	747,978	690,437	4,189
Allogene Therapeutics EPS beats by $0.05 [2/25/2021 4:35 PM] Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances [Feb-26-21 08:57AM] Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update [Feb-25-21 04:02PM] Allogene Therapeutics, Inc. to Host Earnings Call [Feb-25-21 03:15PM]
04-11-2020	PM	7:30 AM ET (Nov 4)	ALLO	Allogene Therapeutics, Inc.	4,630	-0.52	-0.55	-0.50	Allogene Therapeutics EPS beats by $0.03 [11/4/2020 7:37 AM]	31.16	-2.64 (-7.80%)	29.70	-4.09 (-12.10%)	17.43 - 55.00	3,531,337	568,312	15,410

05-08-2020	PM	7:30 AM ET (Aug 5)	ALLO	Allogene Therapeutics, Inc.	5,090	-0.53	-0.55	-0.41	Allogene Therapeutics EPS beats by $0.01 [8/5/2020 7:34 AM]	38.15	1.07 (2.89%)	37.08	0.0 (0.00%)	17.43 - 55.00	418,694	490,358	6,709

06-05-2020	PM		ALLO	Allogene Therapeutics, Inc.	3,970	-0.50	-0.57	-0.32	Allogene Therapeutics EPS beats by $0.08 [5/6/2020 7:34 AM]	30.86	-0.82 (-2.59%)	0.0	0.0 (0.00%)	17.43 - 33.80	809,439	799,122	0